Research programme: casein kinase II inhibitors - Cylene

Drug Profile

Research programme: casein kinase II inhibitors - Cylene

Alternative Names: CK-5011; CK2 inhibitors; CX-5011; CX-8184

Latest Information Update: 24 Dec 2013

Price : $50

At a glance

  • Originator Cylene Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Casein kinase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Jan 2013 Discontinued - Preclinical for Cancer in USA (PO)
  • 04 Apr 2012 Research programme: casein kinase II inhibitors is still in preclinical development for Cancer in USA
  • 03 Apr 2012 Pharmacodynamics and pharmacokinetics data from preclinical studies presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top